- Home
- MKZR vs ALZN Comparison
MKZR vs ALZN Comparison
Compare MKZR & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKZR
- ALZN
- Stock Information
- Founded
- MKZR 2012
- ALZN 2016
- Country
- MKZR United States
- ALZN United States
- Employees
- MKZR N/A
- ALZN N/A
- Industry
- MKZR
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- MKZR
- ALZN Health Care
- Exchange
- MKZR Nasdaq
- ALZN Nasdaq
- Market Cap
- MKZR 10.3M
- ALZN 9.0M
- IPO Year
- MKZR N/A
- ALZN 2021
- Fundamental
- Price
- MKZR $4.20
- ALZN $2.25
- Analyst Decision
- MKZR
- ALZN Strong Buy
- Analyst Count
- MKZR 0
- ALZN 1
- Target Price
- MKZR N/A
- ALZN $42.00
- AVG Volume (30 Days)
- MKZR 32.1K
- ALZN 132.8K
- Earning Date
- MKZR 11-14-2025
- ALZN 12-11-2025
- Dividend Yield
- MKZR 24.69%
- ALZN N/A
- EPS Growth
- MKZR N/A
- ALZN N/A
- EPS
- MKZR N/A
- ALZN N/A
- Revenue
- MKZR $20,994,778.00
- ALZN N/A
- Revenue This Year
- MKZR N/A
- ALZN N/A
- Revenue Next Year
- MKZR N/A
- ALZN N/A
- P/E Ratio
- MKZR N/A
- ALZN N/A
- Revenue Growth
- MKZR 3.63
- ALZN N/A
- 52 Week Low
- MKZR $3.86
- ALZN $1.88
- 52 Week High
- MKZR $50.00
- ALZN $12.11
- Technical
- Relative Strength Index (RSI)
- MKZR 38.42
- ALZN 44.47
- Support Level
- MKZR $3.92
- ALZN $1.88
- Resistance Level
- MKZR $4.86
- ALZN $2.35
- Average True Range (ATR)
- MKZR 0.41
- ALZN 0.18
- MACD
- MKZR -0.05
- ALZN -0.02
- Stochastic Oscillator
- MKZR 20.88
- ALZN 42.65
About MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.